Catalyst Calendar

Thu, Jul 9, 2026

1 updates

IRD

7:00 AM

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Trial Results • Phase 1/2Cohort 1 topline data Wed, Sep 9, 2026, 7:00 AM EDTopusgtx.com

Mon, Jul 6, 2026

1 updates

IRD

7:00 AM

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Trial Design Update • Phase 3Trial update Mon, Jul 6, 2026, 7:00 AM EDTopusgtx.com

Fri, Jun 26, 2026

1 updates

IRD

9:15 AM

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

opusgtx.com

Tue, Jun 16, 2026

1 updates

IRD

4:05 PM

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Trial Results • Phase 1/2Topline data Tue, Sep 1, 2026, 4:05 PM EDTopusgtx.com

Tue, Jun 2, 2026

1 updates

IRD

7:00 AM

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Results CallResults call Tue, Jun 16, 2026, 10:00 AM ETopusgtx.com

Thu, May 28, 2026

1 updates

IRD

4:01 PM

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

opusgtx.com

Wed, May 27, 2026

1 updates

IRD

8:00 AM

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

opusgtx.com

Wed, May 13, 2026

1 updates

IRD

7:00 AM

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

opusgtx.com

Tue, May 12, 2026

1 updates

IRD

7:00 AM

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Trial Results • Phase 1/2OPGx-BEST1 Cohort 1 topline data Tue, Sep 1, 2026, 10:00 AM ETopusgtx.com

Thu, May 7, 2026

2 updates

IRD

4:30 PM

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Presentation / Abstract • Phase 1/2opusgtx.com

IRD

7:00 AM

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Enrollment • Phase 1/2opusgtx.com

Mon, May 4, 2026

1 updates

IRD

4:30 PM

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

opusgtx.com

Mon, Apr 27, 2026

1 updates

IRD

8:00 AM

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Presentation / Abstract • Phase 1opusgtx.com